AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8413073 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-based medical practice
Number of subjects: 0
Study 8413073 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 3812184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 14
Study 3812184 — intervention group
Group type: COMPARATOR
Intervention: Single-rate ventricular pacing
Number of subjects: 14
Study 3812184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pacing modes (ventricular and dual-chamber)
Number of subjects: 14
Study 28547269 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bladder catheterization (CC)
Number of subjects: 184
Study 28547269 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bladder catheterization (IC)
Number of subjects: 184
Study 26699599 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with acute kidney injury (AKI)
Number of subjects: 1406
Study 26699599 — intervention group
Group type: COMPARATOR
Intervention: CABG without acute kidney injury (AKI)
Number of subjects: 1406
Study 24206528 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular hypothermia combined with thrombolysis
Number of subjects: 400
Study 24206528 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 400
Study 22198532 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hand training with 30° clockwise cursor rotation
Number of subjects: 0
Study 22198532 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hand training with 30° clockwise cursor rotation
Number of subjects: 0
Study 22198532 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20167144 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 1 (96 actuations, 24 days)
Number of subjects: 254
Study 20167144 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 2 (120 actuations, 30 days)
Number of subjects: 254
Study 20167144 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 3 (128 actuations, 32 days)
Number of subjects: 254
Study 20167144 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol pMDI without actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Run-in period
Number of subjects: 254
Study 18062023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined electric, electromagnetic, quantum and microvibration therapy with basic treatment (antiaggregants, beta-blockers, statins)
Number of subjects: 150
Study 18062023 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy with basic treatment (antiaggregants, beta-blockers, statins)
Number of subjects: 150
Study 18062023 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment without physiotherapy
Number of subjects: 150
Study 16236892 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem/tobramycin
Number of subjects: 102
Study 16236892 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime/tobramycin
Number of subjects: 102
Study 16236892 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label meropenem/tobramycin
Number of subjects: 102
Study 16236892 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (meropenem/tobramycin, ceftazidime/tobramycin, open-label meropenem/tobramycin)
Number of subjects: 102
Study 12134936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml of 1% lidocaine injected into the carotid sinus nerve
Number of subjects: 92
Study 12134936 — intervention group
Group type: COMPARATOR
Intervention: No injection of lidocaine
Number of subjects: 92
Study 10195549 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/kg propofol
Number of subjects: 20
Study 10195549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sevoflurane
Number of subjects: 20
Study 7540039 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB/BEP
Number of subjects: 234
Study 7540039 — intervention group
Group type: COMPARATOR
Intervention: BEP
Number of subjects: 234
Study 1332625 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-121
Number of subjects: 0
Study 1332625 — intervention group
Group type: EXPERIMENTAL
Intervention: DWA-2114R
Number of subjects: 0
Study 1332625 — intervention group
Group type: EXPERIMENTAL
Intervention: 254-S
Number of subjects: 0
Study 1332625 — intervention group
Group type: COMPARATOR
Intervention: 254-S plus VDS
Number of subjects: 0
Study 1332625 — intervention group
Group type: COMPARATOR
Intervention: CDDP plus VDS
Number of subjects: 0
Study 4061377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg I.V. before therapy, and 4 mg I.V. q 4 h X 6 doses)
Number of subjects: 19
Study 4061377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30045185 — intervention group
Group type: EXPERIMENTAL
Intervention: EXC 001 (5 mg/cm)
Number of subjects: 23
Study 30045185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 25852193 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Statistical Iterative Reconstruction (ASIR) protocol (n=64)
Number of subjects: 122
Study 25852193 — intervention group
Group type: COMPARATOR
Intervention: Standard Filtered Back Projection (FBP) protocol (n=58)
Number of subjects: 122
Study 26214544 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐PC (motivational-interviewing with patient choice)
Number of subjects: 500
Study 26214544 — intervention group
Group type: COMPARATOR
Intervention: MI‐IOP (motivational-interviewing focused on engagement in an IOP)
Number of subjects: 500
Study 26214544 — intervention group
Group type: COMPARATOR
Intervention: No further outreach
Number of subjects: 500
Study 23509000 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic model
Number of subjects: 60
Study 23509000 — intervention group
Group type: COMPARATOR
Intervention: Static computer-based module (Key Views)
Number of subjects: 60
Study 23509000 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality computer-based module
Number of subjects: 60
Study 20870113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 15.0 mg/mL (1.5%)
Number of subjects: 42
Study 20870113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 30.0 mg/mL (3.0%)
Number of subjects: 42
Study 20870113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 0.15 to 5.00 mg/mL (0.015% to 0.500%)
Number of subjects: 42
Study 18812761 — intervention group
Group type: EXPERIMENTAL
Intervention: McCarey-Kaufman (MK) medium
Number of subjects: 18
Study 18812761 — intervention group
Group type: COMPARATOR
Intervention: Organ culture (OC)
Number of subjects: 18
Study 16615926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose magnesium sulfate (50 mg/kg load and 2 g/h)
Number of subjects: 120
Study 16615926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose magnesium sulfate (25 mg/kg load and 1 g/h)
Number of subjects: 120
Study 16615926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16615926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose magnesium sulfate
Number of subjects: 120
Study 16615926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose magnesium sulfate
Number of subjects: 120
Study 12791810 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FECNT PET scanning in healthy subjects
Number of subjects: 11
Study 12791810 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FECNT PET scanning in early-stage unilateral PD patients
Number of subjects: 11
Study 12791810 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FECNT PET scanning in late-stage PD patients
Number of subjects: 11
Study 11009288 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0
Study 11009288 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 7626347 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 106
Study 7626347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 2199622 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil, doxorubicin (Adriamycin), and mitomycin (FAM)
Number of subjects: 281
Study 2199622 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 281
Study 229707 — intervention group
Group type: EXPERIMENTAL
Intervention: FOY injectable
Number of subjects: 201
Study 229707 — intervention group
Group type: COMPARATOR
Intervention: Trasylol
Number of subjects: 201
Study 229707 — intervention group
Group type: EXPERIMENTAL
Intervention: FOY-305 oral capsule
Number of subjects: 201
Study 229707 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 201
Study 31343948 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) supplementation
Number of subjects: 23
Study 31343948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic BJ supplementation
Number of subjects: 23
Study 31343948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic nitrate-depleted beetroot juice (NDBJ) supplementation
Number of subjects: 23
Study 31343948 — intervention group
Group type: EXPERIMENTAL
Intervention: BJ and NDBJ supplementation
Number of subjects: 23
Study 28647340 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient specific training using 3D printed aneurysms
Number of subjects: 10
Study 28647340 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine procedure without simulator training)
Number of subjects: 10
Study 25752903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BII: Initial bolus plus early start of the intermittent infusion
Number of subjects: 18
Study 25752903 — intervention group
Group type: COMPARATOR
Intervention: Group DII: No bolus plus delayed start (8 h) of the intermittent infusion
Number of subjects: 18
Study 23635846 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTp (Cognitive Behavioural Therapy) + TAU (Treatment as Usual)
Number of subjects: 45
Study 23635846 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (Control)
Number of subjects: 45
Study 21503861 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care (IC) model
Number of subjects: 481
Study 21503861 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care (CG)
Number of subjects: 481
Study 17879970 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic communication skills training program
Number of subjects: 0
Study 17879970 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training program with consolidation workshops
Number of subjects: 0
Study 17879970 — intervention group
Group type: COMPARATOR
Intervention: Physicians' communication skills (breaking bad news)
Number of subjects: 0
Study 17879970 — intervention group
Group type: COMPARATOR
Intervention: Self-reported distress by patients and relatives
Number of subjects: 0
Study 16490974 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I)
Number of subjects: 5
Study 16490974 — intervention group
Group type: COMPARATOR
Intervention: Iodine-free product
Number of subjects: 5
Study 14499051 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 729
Study 14499051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study 10718501 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 39876
Study 10718501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 39876
Study 10718501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for aspirin)
Number of subjects: 39876
Study 10718501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for vitamin E)
Number of subjects: 39876
Study 9197297 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine 1% (30 ml)
Number of subjects: 12
Study 9197297 — intervention group
Group type: COMPARATOR
Intervention: 2-chloroprocaine 3% (10 ml)
Number of subjects: 12
Study 7507933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 32
Study 7507933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 32
Study 7507933 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with Lorazepam
Number of subjects: 32
Study 7507933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3569828 — intervention group
Group type: COMPARATOR
Intervention: 3 ml 5% tylose
Number of subjects: 50
Study 3569828 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms sulprostone gel
Number of subjects: 50
Study 3569828 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms sulprostone gel
Number of subjects: 50
Study 3569828 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml 2.5 mM calcium chloride gel
Number of subjects: 50
Study 3569828 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml 9.0 mM calcium chloride gel
Number of subjects: 50
Study 3569828 — intervention group
Group type: EXPERIMENTAL
Intervention: sulprostone
Number of subjects: 50
Study 3569828 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium chloride gel
Number of subjects: 50
Study 29627621 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (flexible take-home doses)
Number of subjects: 276
Study 29627621 — intervention group
Group type: COMPARATOR
Intervention: Methadone (daily witnessed ingestion)
Number of subjects: 276
Study 26707685 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate
Number of subjects: 178
Study 26707685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 25343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 90
Study 25343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio (WHtR)
Number of subjects: 90
Study 25343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 90
Study 22971323 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric albendazole every 3 months plus praziquantel annually
Number of subjects: 948
Study 22971323 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 948
Study 22971323 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric albendazole plus praziquantel
Number of subjects: 948
Study 20795922 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise
Number of subjects: 60
Study 20795922 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 60
Study 20795922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Progressive resistance exercise and Aerobic exercise)
Number of subjects: 60
Study 18948442 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strength training of the neck/shoulder muscles
Number of subjects: 42
Study 18948442 — intervention group
Group type: COMPARATOR
Intervention: General fitness training performed as leg bicycling
Number of subjects: 42
Study 18948442 — intervention group
Group type: COMPARATOR
Intervention: Reference intervention without physical activity
Number of subjects: 42
Study 16167129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg)
Number of subjects: 0
Study 16167129 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 0
Study 12699023 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy and nicotine patch
Number of subjects: 121
Study 12699023 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcessation self-efficacy
Number of subjects: 121
Study 10226092 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers and amiodarone
Number of subjects: 4
Study 10226092 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers alone
Number of subjects: 4
Study 10226092 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 4
Study 10226092 — intervention group
Group type: COMPARATOR
Intervention: Neither beta-blockers nor amiodarone
Number of subjects: 4
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 6 ml h‐1
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 8 ml h‐1
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 10 ml h‐1
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 12 ml h‐1
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 14 ml h‐1
Number of subjects: 151
Study 8688255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative extradural infusion)
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: All ropivacaine infusion groups
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (end of study)
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ropivacaine infusion rates
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rates of ropivacaine
Number of subjects: 151
Study 8688255 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 151
Study 1676364 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0
Study 1676364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Number of subjects: 0
Study 6219403 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal muscle strength training (12-session training program)
Number of subjects: 25
Study 6219403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 25
Study 30047838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social power state
Number of subjects: 0
Study 30047838 — intervention group
Group type: COMPARATOR
Intervention: High social power state
Number of subjects: 0
Study 30047838 — intervention group
Group type: COMPARATOR
Intervention: Neutral social power state
Number of subjects: 0
Study 30096639 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 40
Study 30096639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27706777 — intervention group
Group type: EXPERIMENTAL
Intervention: New SSR markers developed for Capsicum, specifically 144 SSR markers tested on cultivated and wild species.
Number of subjects: 48
Study 27706777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-species transferability of 91 SSR markers tested on seven cultivated and wild Capsicum species.
Number of subjects: 48
Study 25262145 — intervention group
Group type: EXPERIMENTAL
Intervention: Wahakura
Number of subjects: 200
Study 25262145 — intervention group
Group type: COMPARATOR
Intervention: Bassinet
Number of subjects: 200
Study 25262145 — intervention group
Group type: EXPERIMENTAL
Intervention: Wahakura and Bassinet
Number of subjects: 200
Study 22098257 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing and case management program
Number of subjects: 407
Study 22098257 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 407
Study 18774743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (DA) as monotherapy
Number of subjects: 0
Study 18774743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (DA) as adjunctive therapy
Number of subjects: 0
Study 18774743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (DA)
Number of subjects: 0
Study 18774743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18774743 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study 17335818 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1,500 mg/d)
Number of subjects: 61
Study 17335818 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetyl cysteine (1.8 g/d)
Number of subjects: 61
Study 15470328 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rabeprazole once daily
Number of subjects: 15
Study 15470328 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole twice daily
Number of subjects: 15
Study 15470328 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole 4 times daily
Number of subjects: 15
Study 15470328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11162336 — intervention group
Group type: EXPERIMENTAL
Intervention: Community action intervention
Number of subjects: 20
Study 9678535 — intervention group
Group type: EXPERIMENTAL
Intervention: Small iodine supplements (Thyrojod depot tablets containing 1530 microg iodide) every 2 weeks for 2 years followed by once weekly for 2 years.
Number of subjects: 117
Study 9678535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iodine supplements).
Number of subjects: 117
Study 9678535 — intervention group
Group type: EXPERIMENTAL
Intervention: Small iodine supplements (Thyrojod depot tablets containing 1530 microg iodide).
Number of subjects: 117
Study 8034818 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Diet (VLCD) - 420-kcal/day liquid diet for 16 weeks, then 1,200-kcal/day diet
Number of subjects: 49
Study 8034818 — intervention group
Group type: COMPARATOR
Intervention: Balanced Deficit Diet (BDD) - 1,200-kcal/day diet throughout treatment
Number of subjects: 49
Study 8034818 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Diet (VLCD)
Number of subjects: 49
Study 8034818 — intervention group
Group type: COMPARATOR
Intervention: Balanced Deficit Diet (BDD)
Number of subjects: 49
Study 2648767 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐300 mg/day of trazodone
Number of subjects: 48
Study 2648767 — intervention group
Group type: COMPARATOR
Intervention: 200‐300 mg/day trazodone plus 1 ampoule (1000 gamma of lipidic phosphorous) twice daily of hypothalamic phospholipids (HPL)
Number of subjects: 48
Study 29696945 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing-gum (group A)
Number of subjects: 22
Study 29696945 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 22